Evidence map›Paper›PMID 42558506›Full record

ArticleFrontiers in cell and developmental biology2026

Conditional deletion of

Valentina Daponte, Chandra Gavva, David J Kapfhamer, Joseph Roberts, Katrin Henke, Hicham Drissi

Abstract read
In one paragraph

Article in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Valentina DaponteDepartment of Orthopaedics, School of Medicine, Emory University, Atlanta, GA, United States.
Chandra GavvaDepartment of Orthopaedics, School of Medicine, Emory University, Atlanta, GA, United States.
David J KapfhamerDepartment of Orthopaedics, School of Medicine, Emory University, Atlanta, GA, United States.
Joseph RobertsCollege of Health Solutions, Arizona State University, Phoenix, AZ, United States.
Katrin HenkeDepartment of Orthopaedics, School of Medicine, Emory University, Atlanta, GA, United States.
Hicham DrissiDepartment of Orthopaedics, School of Medicine, Emory University, Atlanta, GA, United States.

Funding

Bone anabolic effects of osteoclast-produced phospho-Wnt5aR56AR080718 · NIAMS · EMORY UNIVERSITY · PI DRISSI, MOULAY HICHAM · 2023 to 2023
$313k
NIAMS NIH HHS R56 AR080718
6 · The paper itself

Abstract

Introduction: Bone remodeling depends on coordinated signaling between bone-resorbing osteoclasts and bone-forming osteoblasts through locally secreted coupling factors. Disruption of this balance leads to decreased bone mass, resulting in conditions such as osteoporosis. Osteoclast-derived anabolic factors, or clastokines, have emerged as attractive therapeutic candidates with the potential of selectively enhancing bone formation without suppressing resorption. Osteoblast-derived WNT5A is an established coupling factor promoting osteoclastogenesis; however, osteoclast-derived WNT5A specific contribution to bone homeostasis and the downstream mechanism by which it acts on osteoblasts remains undefined. Methods: This study aimed to address this gap using a myeloid-specific conditional knockout mouse that selectively targets osteoclast-derived WNT5A while leaving osteoblast-derived WNT5A intact. Wnt5a was conditionally deleted in osteoclast precursors and their progeny using LysM-Cre; Wnt5aF/F mice and both male and female knockout mice were characterized by μCT, histomorphometry, serum bone turnover markers, transcriptomic profiling of osteoblast-enriched cells, and in vitro focal adhesion and migration assays. Results: Both male and female knockout mice displayed significantly reduced trabecular volume compared with controls. This low bone mass phenotype was driven by decreased osteoblast number and activity, with no significant changes in osteoclast number or resorptive function. Transcriptomic profiling of osteoblast-enriched cells revealed dysregulation of genes involved in focal adhesion, integrin binding, and cell communication, alongside upregulation of stress-related gene networks. Histological and functional analyses demonstrated that loss of osteoclast-derived WNT5A impaired extracellular matrix maturation and disrupted osteoblast focal adhesion assembly and migration. Discussion: Together, our study establishes osteoclast-derived WNT5A as a clastokine that promotes bone formation in vivo by regulating osteoblast migration and adhesion dynamics. These findings establish a mechanistic link between osteoclast secretory activity and osteoblast function and highlight the context-dependent and cell-of-origin specific roles of WNT5A in skeletal homeostasis.

Indexed as

clastokinecouplingosteoblastsosteoclastsWnt5a

Identifiers

PMID42558506
PMCPMC13437647

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.